Anti-TIGIT Antibody Blocking for Restoring Anti-Tumor T Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer immunotherapy methods fail to effectively activate the immune system against tumor cells due to elevated expression of TIGIT, a co-inhibitory receptor on T cells, leading to suppressed immune responses.

Innovation Solution

Development of an anti-TIGIT antibody that binds to TIGIT, blocking its inhibitory action and enhancing effector T cell function, regulating Treg activity, and increasing cytokine secretion.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If TIGIT expression is elevated on T cells, then immune suppression increases, but immune response against tumor cells decreases

Engineering Contradiction:

Improveimmune suppressionVSAvoidimmune response against tumor cells

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent uses an anti-TIGIT antibody as an intermediary substance that binds to the TIGIT receptor on T cells, blocking its interaction with ligands and thereby preventing the inhibitory signal transmission. This mediator approach directly counteracts the harmful immune suppression caused by elevated TIGIT expression while restoring effective anti-tumor immune responses

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the functional state of TIGIT by introducing an antibody that modifies the receptor-ligand interaction parameter. By binding to TIGIT, the antibody alters the signaling parameter from inhibitory to permissive, thereby converting the suppressed immune response into an active anti-tumor response without changing the TIGIT expression level itself

Inventive Principle:

Principle #35Parameter changes

2Strength

If TIGIT binds to its ligand, then T cell inhibition is enhanced, but effector T cell function is suppressed

Engineering Contradiction:

ImproveT cell inhibitionVSAvoideffector T cell function

Core Design Contradiction:

StrengthVSPower

Solution Approach 1:

The anti-TIGIT antibody acts as a counterweight to the inhibitory TIGIT-ligand interaction. By binding to TIGIT, the antibody provides an opposing force that balances and neutralizes the inhibitory signal, thereby restoring effector T cell function without completely eliminating TIGIT expression or its physiological roles

Inventive Principle:

Principle #8Anti-weight (Counterweight)

3Object-affected harmful factors

If Treg cells express TIGIT, then immunosuppressive activity increases, but immune system activation decreases

Engineering Contradiction:

Improveimmunosuppressive activityVSAvoidimmune system activation

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The antibody serves as a mediator that specifically targets TIGIT on Treg cells, blocking their immunosuppressive function. By intervening in the TIGIT-ligand interaction on Treg cells, the antibody prevents excessive immunosuppression while allowing necessary immune system activation against tumor cells

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12558406B2Anti-TIGIT antibodies and use thereof

Publication Date: 2026.02.24 MEDIMABBIO INC

AI summary

The present invention relates to: novel anti-TIGIT antibodies; and uses thereof for increasing immunity, anticancer treatments, and preventing and/or treating immunological diseases.